

Ovarian Cancer (Epithelial) Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

Pathology: _____ Stage: _____

Line of Therapy: __Neoadjuvant/Pre-Op __Adjuvant/Post-Op ECOG Performance Status: _____ ICD-10 Code: _____

__1st Line __2nd Line __3rd Line __3rd Line+ __Maintenance

Biomarkers/Characteristics: (Select all that apply)

BRCA1 Status: __Germline Mutation __Wild Type (no mutation) Platinum Sensitive*: __Yes __No __Not Reported

__Somatic Mutation __Not Reported

Platinum Refractory/Resistant: __Yes __No __Not Reported

BRCA2 Status: __Germline Mutation __Wild Type (no mutation)

__Somatic Mutation __Not Reported

Adjuvant Therapy | Stage IA/B (Grade 2 or 3) or IC (Grade 1-3)

__ Carboplatin and dose dense paclitaxel

__ Carboplatin and paclitaxel

Adjuvant or Primary Therapy | Stage II, III, IV

__ Carboplatin and paclitaxel (**Administered weekly or every 3 weeks**)

__ Intravenous (IV) paclitaxel and Intraperitoneal (IP) cisplatin and IP paclitaxel (**Stage III only**)

Recurrent Disease | First and Subsequent Lines of Therapy (1st Line+) | Platinum-Sensitive*

__ Carboplatin

__ Carboplatin and gemcitabine (Gemzar)

__ Carboplatin and paclitaxel

__ Carboplatin and weekly paclitaxel

Recurrent Disease | Maintenance Therapy | Platinum-Sensitive*

__ Niraparib (Zejula)

__ Olaparib (Lynparza)

__ Rucaparib (Rubraca)

Recurrent Disease | Second and Subsequent Lines of Therapy (2nd Line+) | Platinum Resistant

__ Bevacizumab (Avastin) monotherapy

__ Docetaxel (Taxotere)

__ Gemcitabine (Gemzar)

__ Liposomal doxorubicin (Doxil or Lipodox)

__ Paclitaxel (weekly)

__ Paclitaxel and bevacizumab (Avastin)

__ Tamoxifen

__ Topotecan (Hycamtin)

__ Topotecan (Hycamtin) and bevacizumab (Avastin)

__ Vinorelbine (Navelbine)

*Platinum sensitive disease is defined as recurrence of greater than 6 months after prior platinum-based therapy

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

